Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer
NCT ID: NCT01400399
Last Updated: 2015-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
84 participants
OBSERVATIONAL
2010-08-31
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Joint Committee on Cancer (AJCC) DCIS or Stage T1- T2, N0 histologically confirmed invasive carcinoma of the breast treated with partial mastectomy with axillary evaluation as appropriate, axillary node dissection or sentinel node biopsy (SLN). Patients with DCIS with or without SLN or axillary node dissection are eligible. Patients greater than 70 years old, with stage 1 disease who are estrogen/progesterone receptor positive (ER/PR+), with or without SLN or axillary node dissection are also eligible.
* Partial mastectomy with or without reconstruction consisting of local tissue rearrangement and/or reduction mammoplasty (ipsilateral and bilateral). Patients who have undergone surgery and/or chemotherapy prior to treatment with radiation therapy are still eligible for enrollment and all evaluations and photographs will begin prior to radiation. Retrospective Placement of at least 3 surgical clips in the lumpectomy cavity is strongly encouraged. Retrospective data may be collected on women who have completed their entire course of treatment as long as they are formally consented.
* Unifocal breast cancer which may be encompassed by excision of a single portion of breast tissue.
* Negative inked histologic margins of partial mastectomy or re-excision specimen to be confirmed prior to radiation. Positive margins are unacceptable. Every effort should be made by the surgeon to obtain negative margins with the initial excision.
* Negative post-partial mastectomy mammography (if malignancy associated micro-calcifications were initially present.)
* Tamoxifen or Arimidex therapy is allowed. If chemotherapy is administered prior to radiation (but following surgery), then a minimum of two weeks must elapse prior to the start of radiation therapy.
* The patient must be 50 years of age or older.
* Signed study-specific informed consent form prior to study entry.
Exclusion Criteria
* Patients who are node positive.
* Patients with distant metastases.
* Palpable or radiographically suspicious contralateral axillary, supraclavicular, infraclavicular or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor.
* Any previously treated contralateral breast carcinoma or synchronous ipsilateral breast carcinoma.
* Prior non-hormonal therapy or radiation therapy for the current breast cancer; prior chemotherapy if administered less than two weeks from the start of therapy.
* Patients with Paget's disease of the nipple.
* Patients with prior breast reconstructive surgery including breast mastopexy or breast augmentation.
* Patients with skin involvement, regardless of tumor size.
* Patients with collagenous diseases, specifically systemic lupus erythematosis, scleroderma or dermatomyositis.
* Patients with severe peripheral vascular disease or coronary artery disease (ex. Previous acute myocardial infarction requiring stents or coronary artery bypass graft within past two years; prior bypass graft of any type etc.)
* Patients with co-existing medical conditions with life expectancy less than 5 years.
* Patients with psychiatric disorders that would preclude obtaining informed consent.
* Other malignancy except non-melanomatous skin cancer less than 5 years prior to participation in this study; the disease free interval from any prior carcinoma must be continuous.
* Patients who are pregnant or lactating.
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
New Hanover Regional Medical Center
OTHER
Coastal Carolina Radiation Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Nichols, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Coastal Carolina Radiation Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Atlantic Radiation Oncology
Supply, North Carolina, United States
Coastal Carolina Radiation Oncology
Wilmington, North Carolina, United States
Zimmer Cancer Center
Wilmington, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZCC-2010
Identifier Type: -
Identifier Source: org_study_id